Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 5/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183803 | 0.78 | ADORA3 (0.51) | P2RX3MAPT | |
| SCHEMBL4181911 | 0.77 | MAPT (0.42) | TP53MAPT | |
| SCHEMBL4173690 | 0.77 | ADORA3 (0.50) | P2RX3MAPT | |
| SCHEMBL4179942 | 0.76 | SMN1; SMN2 (0.41) | P2RX3TP53MAPT | |
| SCHEMBL4079500 | 0.73 | CLPP (0.43) | CLPPCCR2P2RX3GRIN1GRIN2B | |
| SCHEMBL4164606 | 0.73 | TSHR (0.42) | P2RX3TP53MAPT | |
| SCHEMBL4171957 | 0.72 | AVPR2 (0.41) | P2RX3TP53MAPT | |
| SCHEMBL3589574 | 0.70 | CTSK (0.48) | CLPPCCR2CFTRP2RX3 | |
| SCHEMBL26705465 | 0.70 | CLPP (0.71) | CLPPCCR2P2RX3 | |
| SCHEMBL26704966 | 0.70 | CLPP (0.61) | CLPPCCR2CFTRP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | claimed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | GABRB1, GRPR, GIPR | CLPP 4755/4885CCR2 3330/4885DPP4 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.